Clinical trials: Autoimmune Disorders
Relapsing Remitting Multiple Sclerosis
Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)
Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)
- Trial name
- NCT02258217
- Testing
- Acthar
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- OhioHealth
Healthy, Primary Immune Thrombocytopenia
A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
This phase 1 single ascending dose study will provide a first in human assessment of safety and tolerability of PF-06755347 in healthy adult males as well as adult males and females with Immune Thrombocytopenia (ITP).
- Conditions
- Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Trial name
- NCT03275740
- Testing
- PF-06755347 intravenous healthy participant, PF-06755347 subcutaneous healthy participant, PF-06755347 subcutaneous ITP
- Where
- 6 sites in United States, Belgium and 3 more
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Pfizer
Multiple Sclerosis
Safety of Switching From Rituximab to Ocrelizumab in MS Patients
This is a prospective between and within group observational study to determine differences in tolerability, immunogenicity and safety related outcomes for 100 multiple sclerosis (MS) patients who have been administered at least…
- Trial name
- NCT02980042
- Testing
- Ocrelizumab, Rituximab
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis, Relapsing-remitting
Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health
This is a pilot study of oral vitamin D supplementation to determine if patients with Multiple Sclerosis (MS) and healthy individuals attain a similar increase in serum 25-hydroxyvitamin D levels.
- Trial name
- NCT01667796
- Testing
- Vitamin D3
- Where
- 2 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Fatigue, Lupus Erythematosus, Systemic
Acupressure for Fatigue in Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by involvement of multiple organs with a female to male ratio of 12:1 with the highest incidence reported in women of child bearing age (15-44…
- Conditions
- Fatigue, Lupus Erythematosus, Systemic, Pain, Chronic, Quality of Life
- Trial name
- AcuSLE (NCT03200548)
- Testing
- Relaxing acupressure plus usual care, Usual care, Stimulating acupressure plus usual care
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Suzanna Zick
Rheumatoid Arthritis
Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept
This study will establish a normative database of Tilmanocept Uptake Values (TUVjoint) in healthy controls age-matched to the RA population.
- Trial name
- NCT04947137
- Testing
- Tc99m tilmanocept
- Where
- 7 sites in United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Navidea Biopharmaceuticals
Type 1 Diabetes
Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes
Insulin resistance (IR) is an important contributor to increased cardiovascular disease risk in type 1 diabetes (T1D). Non-esterified fatty acid elevation is a significant contributor to IR in T1D and may be a target of…
- Trial name
- AcT1 (NCT01816165)
- Testing
- Acipimox
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Vitamin B12 Deficiency
Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients
A review of the literature reveals that very few studies have assessed the potential co-existence of vitamin B12 deficiency due to gastric parietal cell autoantibodies. While Segal et al.
- Trial name
- NCT01876329
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Keesler Air Force Base Medical Center
Parkinson's Disease, Multiple Sclerosis
Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients
Fatigue is one of the most common and debilitating symptoms experienced in Parkinson's Disease (PD) and Multiple Sclerosis (MS).
- Trial name
- PDMSLac (NCT02184494)
- Testing
- pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Florida State University
Diabetic Ketoacidosis, Type 1 Diabetes Mellitus
Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes
A frequent complication in the management of diabetic ketoacidosis (DKA) in children with type 1 diabetes is rebound hyperglycemia (blood glucose over 180 mg/dL) which increases the risk of re-developing DKA and can lengthen the…
- Trial name
- NCT03107208
- Testing
- Glargine, Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
This is a phase 1, randomized, placebo-controlled, double-blind, single ascending dose study of IV VIS649 in healthy subjects. VIS649 is a monoclonal immunoglobulin G2 (IgG2) antibody targeting the B-cell growth factor APRILL.
- Conditions
- Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy, IgA Nephropathy
- Trial name
- NCT03719443
- Testing
- VIS649
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Multiple Sclerosis
Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY
The primary purpose of this single center, randomized, open label study in relapsing Multiple Sclerosis (MS) patients on PLEGRIDY (peginterferon beta-1a) is to assess the effect of Preparation H (phenylephrine) Maximum Strength…
- Trial name
- NCT02665221
- Testing
- No Treatment Arm, Topical Preparation H arm
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Healthy
Study of Belimumab Administered Subcutaneously to Healthy Subjects
The purpose of this study is to measure the amount of belimumab in the blood when given as an injection under the skin (subcutaneously; SC) and to evaluate the safety and tolerability of multiple injections under the skin in…
- Trial name
- NCT01583530
- Testing
- Single Dose Group: Belimumab IV 240 mg, Single Dose Group: Belimumab SC 2 x 120 mg, Single Dose Group: Belimumab SC 1 x 240 mg
- Where
- 4 sites in United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Human Genome Sciences Inc.
Type 1 Diabetes
Three-way, Cross-over Closed-loop Exercise Study
Blood glucose control systems that utilize both insulin and glucagon to manage blood sugar are paving the way to revolutionize the management of this disease.
- Trial name
- NCT02241889
- Testing
- Insulin pump therapy, Closed-loop Artificial Pancreas Controller
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Rheumatoid Arthritis
Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging
Determine the localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects with active RA and concordance with clinical symptomology.
- Trial name
- NCT02683421
- Testing
- Tilmanocept
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Navidea Biopharmaceuticals
Multiple Sclerosis
A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis
This was a Phase 2, randomized, double-blind, placebo-controlled 2 parallel-arm study to assess the effect on serum neurofilament light chain (sNfL), safety and tolerability of oral SAR443820 compared to placebo in male and…
- Trial name
- NCT05630547
- Testing
- SAR443820
- Where
- 35 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study
This is an investigator-initiated, prospective, randomized, multicenter, parallel, open-label, pilot clinical trial evaluating the efficacy of TI for PPBG, PPGE, and time-in-range on CGM download in patients with T1D.
- Trial name
- STAT (NCT03143816)
- Testing
- Technosphere insulin
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Rheumatoid Arthritis, Psoriatic Arthritis
Impact of Cannabis on Pain and Inflammation Among Patients With Rheumatoid or Psoriatic Arthritis
This laboratory study will investigate the impact of cannabis on pain, affect, and inflammation among patients with rheumatoid or psoriatic arthritis (n = 76).
- Trial name
- NCT04269993
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Brown University
Multiple Sclerosis
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
The purpose of this study is to evaluate the feasibility of [18F]Florbetapir positron emission tomography (PET) for assessment of demyelination in the patients with relapsing remitting multiple sclerosis.
- Trial name
- NCT01767493
- Testing
- [18F]Florbetapir PET imaging
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Rheumatoid Arthritis
A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes
The main objective of this study is to compare the pharmacokinetics (PK) of the abatacept drug product converted from drug substance by a new drug substance process (Treatment A) relative to the current drug substance process…
- Trial name
- NCT03714022
- Testing
- Abatacept
- Where
- 2 sites in United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb